Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Blue Jet Healthcare shares rally 9% after Rs 800 crore QIP allotment
Blue Jet Healthcare shares rose sharply on Friday after the company completed its Rs 800 crore QIP, attracting marquee institutional investors, including multiple ICICI Prudential Mutual Fund schemes. The fund raise is expected to strengthen the company's balance sheet, support expansion plans, and boost long-term growth prospects while broadening its institutional shareholder base.

Stock Market Today Live, July 9: Sensex up 450 pts, trades at 76,956.50; Nifty up 155 pts; Sun Pharma, SBI Life, Bajaj Finserv top gainers - BusinessLine
Stock Market Today Live, July 9: Sensex up 450 pts, trades at 76,956.50; Nifty up 155 pts; Sun Pharma, SBI Life, Bajaj Finserv top gainersBusinessLine
Pharma stocks: Lupin, Torrent hit new peaks; Sun nears summit; here's why
Pharma stock rally: Orchid Pharma, Hikal, Unichem Labs, IOL Chemicals, SPARC, RPG Life Sciences and Acutaas Chemicals surged up to 13% in Wednesday's trade.
Poly Medicure among 4 stocks that closed below VWAP
Four Nifty500 stocks, Poly Medicure, Aditya Birla Real Estate, Siemens Energy India, and Onesource Specialty Pharma, closed over 2% below their VWAP on July 3, indicating potential bearish momentum and heightened selling pressure, according to technical scan data.

Healthcare, banks and EVs remain long-term bets: Invesco Mutual Fund's Taher Badshah
Taher Badshah, Chief Investment Officer at Invesco Mutual Fund, expects EV adoption to increase gradually with policy support, while opportunities are emerging in power distribution alongside transmission. Badshah also said SIP inflows remain stable and mutual fund industry trends are not showing signs of concern.
HDFC Mutual Fund buys additional 10 lakh shares of Global Health for Rs 130 crore
HDFC Mutual Fund has secured an additional 10 lakh shares of Global Health, which is known for operating Medanta hospitals, from co-founder Sunil Sachdeva for Rs 130 crore. This acquisition builds on a prior purchase made last month. The transaction accounts for a 0.37% stake in the company. In related news, Global Health has reported an impressive 39.7% increase in its fourth-quarter profit after tax, totaling Rs 141.7 crore.

Hindalco appoints Kapil Agrawal as CEO (Designate) for copper business; Rohit Pathak to move to new role
Hindalco Industries has appointed Kapil Agrawal as CEO (Designate) – Copper with effect from November 1, 2026. He will take over as CEO of the Copper business from March 1, 2027, succeeding Rohit Pathak, who will transition to a new role within the Aditya Birla Group.
HDFC MF, ADIA among buyers as Sepia Investments offloads Rs 749 crore in Corona Remedies via block deal
Sepia Investments and Anchor Partners sold shares worth about Rs 777 crore in Corona Remedies through block deals. HDFC Mutual Fund emerged as the largest buyer, while several institutional investors, including Aberdeen entities, ADIA, Invesco and WhiteOak, also accumulated stakes.
AB Group reaffirms bet on Voda Idea with ₹4,730 Cr infusion
Vodafone Idea shareholders approved a ₹4,730-crore investment from the Aditya Birla Group via preferential allotment of warrants, increasing AB Group's stake to around 13%. Chairman Kumar Mangalam Birla stated the company's focus now shifts to execution across operations, customer service, and network expansion. This capital infusion will support capital expenditure and loan repayment, reinforcing Vi's financial health.
Market Trading Guide: Akums Drugs among 4 stock recommendations for Thursday
Domestic equities ended lower amid global uncertainty and caution ahead of key US inflation data. Despite market weakness, analysts remain bullish on Akums Drugs and Aditya Birla Sun Life AMC after strong technical breakouts, rising volumes and improving momentum indicators.
PE investor BC Investments sells Rs 612 crore stake in Emcure Pharma; Kotak MF picks up stake
Private equity firm BC Investments IV sold a Rs 612 crore stake in Emcure Pharmaceuticals to Kotak Mahindra Mutual Fund at Rs 1,700 per share. Despite this divestment, analysts remain positive on Emcure's growth outlook across its core therapeutic segments.
Sebi may widen 50% overlap rule to thematic passive mutual fund schemes
Curb on number of smart-beta schemes also likely; move aimed at curbing proliferation in segment